# Romania’s Reimbursed Medicines List (GD 720/2008, 2009–2026)

Consolidated as of 1 April 2026 (Government Decision No. 121 of 5 March 2026 (Official Gazette No. 181 of 9 March 2026, in force since 1 April 2026)).
- **Active substances:** 1,183 (1,116 unique ATCs, 1,644 active positions)
- **Growth 2009–2026:** +347 unique ATCs (+45.1%) across 53 updates
- **Historical departures (2009–2026):** 131 active substance dossiers (10 explicitly repealed and 121 withdrawn)
- **Matched commercial brands (ANMDMR 12 Nov 2026):** 919 active dossiers (dispensing: P-RF, P-6L, PR, PS, S, OTC)

## Sublists
- **Sublist A — 90% reimbursement** (90% of reference price): 159 positions. Core outpatient medicines reimbursed at 90% of the reference price.
- **Sublist B — 50% reimbursement (90% low-income pensioners)** (50% of reference price): 228 positions. 50% of the reference price (or 90% — 50% FNUASS + 40% Ministry of Health transfer — for pensioners earning ≤ 2,020 RON/month, up to a 330 RON/month reference-price prescription cap). Under GEO 105/2024, pensioners ≤ 2,020 RON/month regardless of other income pay 10% (90% covered) on prescriptions ≤ 330 RON/month at reference price.
- **Sublist C, Section C1 — Chronic disease groups (G1–G31i), 100%** (100% of reference price): 359 positions. Outpatient medicines reimbursed at 100% of the reference price by coded chronic condition (G1–G31i); specialist initiation required except G1 pos. 2–7, 9 and G10 pos. 15–22.
- **Sublist C, Section C2 — National health programs (P1–P11), 100%** (100% of settlement price): 704 positions. Medicines granted under national curative health programs (oncology, diabetes, HIV/hepatitis, rare diseases, transplant), funded 100% up to the settlement price.
- **Sublist C, Section C3 — Children, pregnant/postpartum women & students (100%)** (100% of reference price): 147 positions. Additional DCIs reimbursed 100% for children (0–18), eligible students/apprentices (18–26), and pregnant/postpartum women (who also receive A, B, C1, and D drugs at 100%).
- **Sublist D — 20% reimbursement** (20% of reference price): 30 positions. Outpatient medicines reimbursed at 20% of the reference price.
- **Sublist E, Section E1 — Vaccines reimbursed 50%** (50% of reference price): 3 positions. Immunological vaccines (influenza & HPV) reimbursed at 50% of the reference price for population groups defined by Ministry of Health Order (added 1 Sep 2023).
- **Sublist E, Section E2 — Vaccines reimbursed 100%** (100% of reference price): 14 positions. Immunological vaccines (flu, HPV, pneumococcal, meningococcal, Tdap, hepatitis B, MMR, varicella) reimbursed at 100% for population groups defined by Ministry of Health Order.

## Statutory Access Markers
- **`*` — Specialist initiation, GP continuation** (44 rows in 2026): Must be initiated by a medical specialist; subsequent prescriptions may be issued by the family doctor based on the specialist's medical letter.
- **`**` — Mandatory therapeutic protocol** (418 rows in 2026): Prescribing and reimbursement require meeting the clinical criteria set in the joint Ministry of Health / CNAS therapeutic protocol.
- **`**^1` — Therapeutic protocol + eligible for day-hospital administration** (312 rows in 2026): Protocol-governed therapy that can also be administered in a day-hospital setting (introduced in March 2017; defined in footnotes B, C1, C2, C3 and also attached to 2 Omalizumabum rows in Sublist A).
- **`^Ω` — CNAS cost-volume contract** (139 rows in 2026): Reimbursement operates under an active CNAS cost-volume managed-entry agreement (introduced in October 2015; defined in B, C1, C2 footnotes and also used on rows in A and C3).
- **`^β` — Cost-volume-outcome contract** (6 rows in 2026): Outcome-based managed-entry agreement tying reimbursement terms to clinical outcomes (active in C1 in 2026; also present historically in C2).
- **`^#` — Framework Contract prescribing rules** (31 rows in 2026): In Sublist B, prescribing rules and caps are governed by the national Health Insurance Framework Contract.
- **`^1` — Restricted to aspirin-intolerant patients** (1 row in 2026): In Sublist A, restricted to patients with documented intolerance to acetylsalicylic acid.
- **`^2` — Only for colonoscopy preparation** (1 row in 2026): In Sublist B, reimbursed solely for pre-colonoscopy bowel preparation.
- **`^3` — Supplied with solvent** (2 rows in 2026): Dispensed together with its reconstitution solvent.
- **`^4` — Imported with ANMDMR special authorization** (24 rows in 2026): Medicines imported under ANMDMR special-needs authorization when no routine marketing authorization exists.
- **`^5` — Only after non-response to prednisone** (2 rows in 2026): Restricted to patients with no therapeutic response to prednisone.

## Chronic Disease Groups (G1–G31i) & National Programs (P1–P11)
- **G1**: Chronic heart failure (NYHA class III or IV) (19 rows)
- **G2**: Patients with valvular and vascular prostheses (1 row)
- **G3**: Percutaneous coronary intervention patients after endovascular stent implantation (2 rows)
- **G4**: Chronic viral hepatitis B, C and D (16 rows)
- **G5**: Autoimmune hepatitis (3 rows)
- **G6**: Primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic cirrhosis (1 row)
- **G7**: Liver cirrhosis (20 rows)
- **G10**: Supportive oncology, hematology and pain therapy (28 rows)
- **G11**: Epilepsy (15 rows)
- **G12**: Parkinson's disease and other neurological disorders (22 rows)
- **G13**: Myasthenia gravis (6 rows)
- **G14**: Multiple sclerosis (4 rows)
- **G15**: Psychiatric disorders (schizophrenia, major affective & acute psychotic disorders; pediatric psychiatric conditions, autism, and ADHD) (26 rows)
- **G16**: Dementias (degenerative, vascular, mixed) (4 rows)
- **G17**: Major collagenoses (SLE, scleroderma, poly/dermatomyositis, systemic vasculitis) (10 rows)
- **G18**: Rheumatoid arthritis, psoriatic arthritis, severe psoriasis, JIA, Still's, uveitis, hidradenitis (13 rows)
- **G19**: Ankylosing spondylitis (3 rows)
- **G22**: Endocrine and metabolic diseases (32 rows)
- **G23**: Wilson's disease (1 row)
- **G25**: Chronic kidney disease — pre-dialysis stage (17 rows)
- **G26**: Chronic ocular diseases (glaucoma, macular, ocular surface & corneal diseases) (19 rows)
- **G27**: Pemphigus (8 rows)
- **G29**: Gaucher disease (4 rows)
- **G30**: Sexually transmitted infections (syphilis, gonorrhea, Chlamydia) (9 rows)
- **G31a**: Inflammatory bowel disease and short bowel syndrome (10 rows)
- **G31b**: Rheumatoid arthritis (biological/targeted) (12 rows)
- **G31c**: Psoriatic arthritis (biological/targeted) (13 rows)
- **G31d**: Axial spondyloarthritis (9 rows)
- **G31e**: Juvenile arthritis (6 rows)
- **G31f**: Severe chronic plaque psoriasis (13 rows)
- **G31g**: Atopic dermatitis and rare dermatological conditions (4 rows)
- **G31h**: Chronic pulmonary diseases (7 rows)
- **G31i**: Autoinflammatory periodic fever syndromes (2 rows)
- **P1**: National communicable diseases program (HIV/AIDS, TB, hepatitis, etc.) (142 rows)
- **P3**: National oncology program (204 rows)
- **P4**: National neurological diseases program (16 rows)
- **P5**: National diabetes program (46 rows)
- **P6**: National rare diseases, hemophilia, thalassemia & severe sepsis program (96 rows)
- **P7**: National endocrine diseases program (19 rows)
- **P9**: National organ, tissue and cell transplantation program (158 rows)
- **P10**: National renal replacement therapy (Dialysis) program (19 rows)
- **P11**: National mental health program (4 rows)